Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique (AVAPAM)
Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique : a Before-and-after Study
This is a prospective, single-centre, quasi-experimental before-and-after study. Women due to give birth at the participating centre will be informed about the study during their 9th-month antenatal appointment. Only expectant mothers for whom cervical ripening is indicated will be included. During the BEFORE period, cervical ripening will be offered to them according to the method chosen by the healthcare team following a discussion of their case at a team meeting. During the AFTER period, the various possible methods of cervical ripening will be offered to the patient, and the choice of method will be left to her.
The participants' experiences will be compared using the QEVA self-assessment questionnaire, completed two days after delivery.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Induction of labour is a common practice in France, and the rate is rising. Cervical ripening and induction of labour are often associated with negative maternal experiences of labour and childbirth. The experience of childbirth has a significant influence on the early mother-child relationship, as well as on the relationship between the parents. A negative experience of childbirth is a major risk factor for postnatal depression and post-traumatic stress disorder.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习联系方式
学习联系方式
- 姓名:Mélanie JUNKE
- 电话号码:0033387179886
- 邮箱:projet-recherche-clinique@chr-metz-thionville.fr
学习地点
-
-
-
Peltre、法国、57245
- CHR METZ-THIONVILLE, Hôpital Femme Mère Enfant
-
接触:
- Mélanie JUNKE
- 电话号码:0033387179886
- 邮箱:projet-recherche-clinique@chr-metz-thionville.fr
-
首席研究员:
- Dr Cristina-Elena DOROFTE, MD
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female patients aged over 18
- Patients who gave their written consent after receiving information to enable them to make an informed decision about the study
- Patients with a medical or non-medical indication for induction of labour who are admitted to the maternity ward of the participating centre
Exclusion Criteria:
- Patients with a history of uterine scarring (a history of uterine scarring is a contraindication to prostaglandins)
- Patients requiring urgent maturation
- Patients requiring induction of labour in connection with a medical termination of pregnancy or foetal death in utero
- Patients who are unable to complete the questionnaire (due to a lack of proficiency in the language, cognitive impairments, etc.)
- Women deprived of their liberty and/or protected by law
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
其他:Period before
|
Cervical ripening will be offered to them in accordance with the approach chosen by the healthcare team following a discussion of her case at a team meeting. |
|
实验性的:Period after
|
Choice of cervical ripening technique from the following: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta®, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon). |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Score of the first dimension of the QEVA questionnaire
大体时间:2 days after giving birth
|
Total score of the dimension: 'emotions during childbirth' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Evaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome. |
2 days after giving birth
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Score of the second dimension of the QEVA questionnaire
大体时间:2 days after giving birth
|
Total score of the dimension 'interactions with healthcare professionals' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome. |
2 days after giving birth
|
|
Score of the third dimension of the QEVA questionnaire
大体时间:2 days after giving birth
|
Total score of the dimension 'first moments with the baby' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 3 to 12, a higher score means a worse outcome. |
2 days after giving birth
|
|
Score of the fourth dimension of the QEVA questionnaire
大体时间:2 days after giving birth
|
Total score of the dimension : 'feeling during the postpartum period' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 4 to 16, a higher score means a worse outcome. |
2 days after giving birth
|
|
Procedures for informing patients about their experience of childbirth
大体时间:2 days after giving birth
|
Multiple choice: 1/information provided by a healthcare professional during a consultation (the patient's referring obstetrician or midwife), 2/our hospital's patient information leaflet, 3/antenatal classes, and 4/other sources (social media, etc.), expressed as percentages of the total number of participants. |
2 days after giving birth
|
|
Impact of the duration of antenatal care on the experience of childbirth
大体时间:At baseline
|
Assessment of the duration of care from the start of maturation to birth (days) |
At baseline
|
|
Impact of the maturation technique used on the experience of childbirth
大体时间:At baseline
|
Assessment of the impact of the ripening technique used on the childbirth experience for the following techniques: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon) |
At baseline
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Cristina-Elena DOROFTE, MD、CHR Metz Thionville Hopital Femme Mère Enfant
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- 2026-02-CHRMT
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.